Labcorp Holdings Inc. $LH Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Labcorp stake by 98.8% in the third quarter, selling 118,118 shares and retaining 1,423 shares valued at approximately $438,000. Institutional investors overall own 95.94% of the company.
• Analysts maintain a “Moderate Buy” consensus on Labcorp, with eight Buy ratings and three Holds and an average price target of $337.73.
• Labcorp reported quarterly EPS of $4.99, beating estimates of $4.78, while revenue rose 5.8% year over year to $3.73 billion. The stock opened at $318.44, and insiders have sold 8,593 shares worth about $2.73 million over the past 90 days.

Curated Wealth Partners LLC decreased its holdings in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 98.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,423 shares of the medical research company's stock after selling 118,118 shares during the quarter. Curated Wealth Partners LLC's holdings in Labcorp were worth $438,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. CoreCap Advisors LLC grew its holdings in Labcorp by 13.8% during the third quarter. CoreCap Advisors LLC now owns 289 shares of the medical research company's stock valued at $89,000 after purchasing an additional 35 shares during the last quarter. Krilogy Financial LLC lifted its position in shares of Labcorp by 2.4% in the 3rd quarter. Krilogy Financial LLC now owns 1,590 shares of the medical research company's stock worth $502,000 after acquiring an additional 37 shares during the period. V Square Quantitative Management LLC grew its holdings in shares of Labcorp by 1.7% during the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company's stock worth $645,000 after purchasing an additional 40 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Labcorp by 4.5% during the 1st quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company's stock worth $272,000 after purchasing an additional 44 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its position in shares of Labcorp by 3.6% during the first quarter. Moss Adams Wealth Advisors LLC now owns 1,364 shares of the medical research company's stock valued at $364,000 after purchasing an additional 47 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LH has been the subject of a number of recent research reports. Robert W. Baird set a $352.00 target price on Labcorp in a research note on Friday, July 31st. UBS Group lifted their price target on shares of Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Piper Sandler boosted their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a "neutral" rating in a report on Tuesday, August 4th. Bank of America increased their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Labcorp from $330.00 to $360.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Labcorp presently has a consensus rating of "Moderate Buy" and an average target price of $337.73.

Insider Activity at Labcorp

In other Labcorp news, EVP Amy B. Summy sold 924 shares of the company's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the sale, the executive vice president directly owned 6,956 shares of the company's stock, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adam H. Schechter sold 4,669 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares of the company's stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,593 shares of company stock valued at $2,733,295 in the last ninety days. Insiders own 0.84% of the company's stock.

Labcorp Stock Performance

Labcorp stock opened at $318.44 on Friday. The firm has a market capitalization of $25.83 billion, a P/E ratio of 18.59, a P/E/G ratio of 1.85 and a beta of 0.87. The stock has a fifty day moving average price of $320.58 and a two-hundred day moving average price of $289.08. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $341.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53.

Labcorp (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same quarter in the previous year, the company earned $4.35 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, analysts anticipate that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

About Labcorp

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing, drug development services and technology-enabled laboratory solutions to healthcare providers, pharmaceutical and biotechnology companies, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including testing related to oncology, women's health, infectious diseases, genetics and genomics.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.